To the content
4 . 2022

Anthropometric, metabolic parameters and cognitive functions investigation in patients with obesity treated with liraglutide 3 mg

Abstract

Obesity is one of the most serious public health problems. Excess adipose tissue, especially visceral tissue, is associated with decreased cognitive function. In this connection, it is relevant to study the possibilities of modern groups of encreatin drugs for correction not only of excess weight but also for improvement of neuroplasticity.

Objective: to evaluate the efficacy and safety of liraglutide 3 mg in obese patients. As well as to evaluate the impact of weight loss in these patients on cognitive functions.

Material and methods. 75 obese patients, including 43 women and 32 men, aged 55–65 years, were examined. Patients signed an informed consent previously approved research protocol by the Ethical Committee of the Siberian State Medical University of the Ministry of Health of Russian Federation (conclusion № 5265 dated 02.05.2017). The study design was prospective comparative and included three visits: First – familiarization with patients, collection of anamnesis, general examination (evaluation of waist circumference, weight), neuropsychological testing (Montreal Cognitive Assessment Scale), administration of liraglutide 6 mg – 1 ml therapy at initial dose of 0.6 mg with subsequent titration weekly to 3 mg. The second and third were administered after 3 and 6 months with evaluation of disease compensation, blood sampling, neuropsychological testing, and correction of therapy. 5 people (3 women and 2 men) dropped out of the study due to unwillingness to buy the drug (costliness), achievement of the desired result, and switching to another drug. No undesirable phenomena were detected.

Results. The study revealed cognitive deficits in the area of memory and visual-constructive functions in obese patients. The use of liraglutide at a maximum dose of 3 mg for 6 months resulted in weight loss. Also it was performed an improvement of cognitive functions in patients with successful weight loss taking liraglutide 3 mg.

Conclusion. The use of liraglutide allows effectively reduce body weight and improve carbohydrate metabolism parameters. Weight loss is the most important factor in improving cognitive function in obese patients.

Keywords:obesity; liraglutide; cognitive disorders

Funding. The study had no sponsor support.

Conflict of interest. The authors declare no conflict of interest.

For citation: Samoilova Iu.G., Matveeva M.V., Oleynik O.A. Anthropometric, metabolic parameters and cognitive functions investigation in patients with obesity treated with liraglutide 3 mg. Endokrinologiya: novosti, mneniya, obuchenie [Endocrinology: News, Opinions, Training]. 2022; 11 (4): 21–5. DOI: https://doi.org/10.33029/2304-9529-2022-11-4-21-25 (in Russian)

References

1. Balasubramanian P., Kiss T., Tarantini S., et al. Obesity-induced cognitive impairment in older adults: a microvascular perspective. Am J Physiol Heart Circ Physiol. 2021; 320 (2): H740–61.

2. Zonneveld M.H., Noordam R., van der Grond J., et al. Interplay of circulating leptin and obesity in cognition and cerebral volumes in older adults. Peptides. 2021; 135: 170424.

3. Lee T.H., Yau S.Y. From obesity to hippocampal neurodegeneration: pathogenesis and non-pharmacological interventions. Int J Mol Sci. 2020; 22 (1): 201.

4. Kivipelto M., Mangialasche F., Ngandu T. Lifestyle interventions to prevent cognitive impairment, dementia and Alzheimer disease. Nat Rev Neurol. 2018; 14 (11): 653–66.

5. Yaribeygi H., Rashidy-Pour A., Atkin S.L., et al. GLP-1 mimetics and cognition. Life Sci. 2021; 264: 118645. DOI: https://doi.org/10.1016/j.lfs.2020.118645

6. Dye L., Boyle N.B., Champ C., et al., The relationship between obesity and cognitive health and decline. Proc Nutr Soc. 2017; 76 (4): 443–54.

7. Bassil F., Fernagut P.O., Bezard E., et al. Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: targets for disease modification? Prog Neurobiol. 2014; 118: 1–18.

8. Grieco M., Giorgi A., Gentile M.C., et al. Glucagon-like peptide-1: a focus on neurodegenerative diseases. Front Neurosci. 2019; 13: 1112.

9. Yildirim Simsir I., Soyaltin U.E., Cetinkalp S. Glucagon like peptide-1 (GLP-1) likes Alzheimer’s disease. Diabetes Metab Syndr. 2018; 12 (3): 469–75.

10. Femminella G.D., Frangou E., Love S.B., et al. Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer’s disease: study protocol for a randomised controlled trial (ELAD study). Trials. 2019; 20 (1): 191.

11. Mansur R.B., Lee Y., Subramaniapillai M., Brietzke E., et al. Cognitive dysfunction and metabolic comorbidities in mood disorders: a repurposing opportunity for glucagon-like peptide 1 receptor agonists? Neuropharmacology. 2018; 136 (pt B): 335–42.

12. Li P.C., Liu L.F., Jou M.J., et al. The GLP-1 receptor agonists exendin-4 and liraglutide alleviate oxidative stress and cognitive and micturition deficits induced by middle cerebral artery occlusion in diabetic mice. BMC Neurosci. 2016; 17 (1): 37.

13. Holscher C. Incretin analogues that have been developed to treat type 2 diabetes hold promise as a novel treatment strategy for Alzheimer’s disease. Recent Pat CNS Drug Discov. 2010; 5 (2): 109–17.

14. Porter D.W., Kerr B.D., Flatt P.R., et al. Four weeks administration of Liraglutide improves memory and learning as well as glycaemic control in mice with high fat dietary-induced obesity and insulin resistance. Diabetes Obes Metab. 2010; 12 (10): 891–9.

15. Carranza-Naval M.J., Del Marco A., Hierro-Bujalance C., et al. Liraglutide reduces vascular damage, neuronal loss, and cognitive impairment in a mixed murine model of Alzheimer’s disease and type 2 diabetes. Front Aging Neurosci. 2021; 13:741923.

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)

CHIEF EDITOR
CHIEF EDITOR
Ametov Alexander S.
Honored Scientist of the Russian Federation, Doctor of Medical Sciences, Professor, Head of Subdepartment of Endocrinology, Head of the UNESCO Network Chair on the subject «Bioethics of diabetes as a global problem» of the Russian Medical Academy of Continuous Professional Education (Moscow)
Вскрытие

Journals of «GEOTAR-Media»